The findings of the present study suggest that NAM administration may act by upregulating NAD+ and Sirt3 expression to increase the antioxidant activity of SOD2 and thereby reduce microglial inflammation and neuronal loss, at least in the MS model. The gene discussed is SOD2; the disease is myeloid sarcoma.